These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23879591)

  • 21. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietic-stimulating agents: the cancer progression controversy and collateral damage to the blood supply.
    Adamson JW
    Transfusion; 2009 May; 49(5):824-6. PubMed ID: 19426200
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic kidney disease, anemia, and epoetin.
    Riley DS
    N Engl J Med; 2007 Mar; 356(9):956; author reply 958-9. PubMed ID: 17329706
    [No Abstract]   [Full Text] [Related]  

  • 24. [Preoperative management of anemia in oncologic surgery].
    Díaz-Cambronero O; Matoses-Jaén S; García-Claudio N; García-Gregorio N; Molins-Espinosa J
    Rev Esp Anestesiol Reanim; 2015 Jun; 62 Suppl 1():45-51. PubMed ID: 26320344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 26. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
    Littlewood TJ
    Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
    [No Abstract]   [Full Text] [Related]  

  • 28. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

  • 29. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietins in oncology.
    Lattanzi SC
    N Engl J Med; 2007 Sep; 357(12):1262; author reply 1262-3. PubMed ID: 17881762
    [No Abstract]   [Full Text] [Related]  

  • 32. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anemia in patients with cancer].
    Kobune M; Kato J; Niitsu Y
    Nihon Rinsho; 2008 Mar; 66(3):524-9. PubMed ID: 18330028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients.
    Gilreath JA; Sageser DS; Jorgenson JA; Rodgers GM
    J Natl Compr Canc Netw; 2008 Jul; 6(6):577-84. PubMed ID: 18597711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anemia, fatigue and aging.
    Balducci L
    Transfus Clin Biol; 2010 Dec; 17(5-6):375-81. PubMed ID: 21067951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S
    Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.